michelcarroll/llama2-earnings-stock-prediction-fine-tune huggingface dataset:
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
Good morning, Heiko. Good to hear from you. 

    Prediction (one of UP, DOWN, SAME): SAME
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
First, we will continue to pursue. We have made investment into digital platform. We are using it, both internally and externally. We have critical customer that depend upon us and we'll continue to trust us for the future. So we are using it to accelerate our growth, be accretive on our growth and our returns. And whether you're getting the right value, I think is up to you to review and give us the multiple expansion that we deserve for these things. We have been so far demonstrating enough margins, sustain margin to this. We anticipate the growth to not come to play visibly in the coming years. And I think our leadership in this is recognized. And yeah, I will expect that this will be turning into a premium for valuation.

    Prediction (one of UP, DOWN, SAME): SAME
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
You're reading that the right way. I think if you -- you have to almost go market by market, because the labor market is such a local issue, but we have -- we've had at the peak six factories that we had what I would characterize as severe labor shortages. That in the time frame late August, early September. Of those, three are now largely cured and three still have some fairly severe shortages that we're working through. And it's not just a lack of hiring, the turnover is elevated right now as well. So if you look at the leading indicators, first leading indicator is applications and those have moved significantly in the right direction. We now need to make sure that we've got the right applicants and then once we've hired and trained, we do a good job of retaining. I don't think we're any different than anybody else in this -- in this particular issue. But it remains challenging, as we work through kind of the -- the egg and the snake as we swallow the impact of this labor shortage through the first quarter, but I would say labor is the most significant aspect of this. It is improving with freight, still a challenge and some ingredients still a challenge.

    Prediction (one of UP, DOWN, SAME): SAME
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
Well, thank you everybody. I'm sure you are looking forward to 2021 as much as we are. Things are starting to break. It looks like on the COVID front still some some challenges ahead. Probably, having talked to our U.S. directors yesterday, they are ahead and things will clear faster than Canada. We see great energy prices. We're encouraged. We're not ready to say they're going to continue indefinitely, but it's a very good start. We're seeing volumes come up. And so, as we close the book on 2020, I want to say thank you to all our people on the phone, our shareholders who stuck with us through 2020, and our staff who were amazingly resilient and allowed us to meet our safety, financial and community objectives, and our customers for working hard with us to keep paying the bills. So, thank you very much and have a great weekend.

    Prediction (one of UP, DOWN, SAME): DOWN
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
Actually both and also for better understanding the mechanism of action of COM701 treatment. The biomarker strategy is broad enough in order to address tumor biopsies and also information gathered from blood samples. We have the component of the retrospective analysis and you also know that we have the component of patient selection basket study in the triplet. We are looking to understand what the tumors are telling us following COM701 treatment, monotherapy or combination and whatever we can get to better understand what's going on in tumor microenvironment remodeling etc. So both goals that you mentioned, but also better understand the mechanism of action.

    Prediction (one of UP, DOWN, SAME): UP
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
Thank you, Marcella.

    Prediction (one of UP, DOWN, SAME): SAME
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
Yeah, it's a good thought. As a theoretical matter, we could support 100% of our needs in that fashion, because that would be all of our excess today, plus an assumption that everything we're producing is going to go through a reinsurance transaction. And for us, obviously that's not necessarily 100% of our business goes through where we can make that assumption at all times. We have to obviously keep a prudential amount of excess. And we also have to be able to warehouse the production that we are generating until we get to that point of distribution with our next ILN. And that's a more difficult one to calibrate. I think it's fair to say that for us this year. we have every expectation that we'll be able to deploy our excess and support -- borrowers in support of our customers and really ultimately in a way that helps to seed our future financial results by generating significant additional growth in our insured portfolio. As we get out beyond 2021, some of those dynamics around distribution versus deployment versus organic generation and what we can harvest from the market may come into more acute focus, but that's not going to be our opportunity in '21.

    Prediction (one of UP, DOWN, SAME): SAME
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
Good morning. Thanks for taking our question. I guess the one on EDIT-101 to start, which patient population do you think is most appropriate for future development in pivotal studies? Would you move forward in both pediatric and adult patients, or would pediatric patients be more appropriate given their disease state?

    Prediction (one of UP, DOWN, SAME): SAME
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
Great question. Generally speaking, what we're seeing both in Australia and more broadly in North America as well is that while commodity prices have recovered, customers are reticent to change their spending plans based on the short-term, medium-term commodity price outlooks. And so I think what we'll have to look for in both markets is announcements from the customer base around their capital spending plans for next year. Obviously, we haven't seen any of those yet, particularly in North America.
But until we see their spending increase, it's hard to see how we're going to see increased occupancy.

    Prediction (one of UP, DOWN, SAME): SAME
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
Okay. And then just last one from me, update on 310 NBP. I think you guys have said part of it would be leased by 2Q and the rest end of the year. Kind of what's the updated timing on that one?

    Prediction (one of UP, DOWN, SAME): DOWN
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
Hi, John.

    Prediction (one of UP, DOWN, SAME): UP
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
Sure. So again, I'll start and then turn it over to Fady and Stuart. As you know, we already reported on interim results from Cohort 1, we did that back at the end of last year. We had some pretty high expectations going into that. And I think admittedly, we believe that the interim Cohort 1 data exceeded those expectations in that a majority of patients achieved clinically meaningful responses at the low end of the planned dose response curve. And we did not have any of those patients have EFs fall below 50%. So we see that as ordering well for the completion of this study, both Cohort 1 and Cohort 2.
And as we are now completed with enrollment in Cohort 2, we'll be preceding toward the database lock and the readout of those results. But as far as how that compares to another compound, keep in mind please that we're running a different study. We're not doing a head to head comparison. We are, however, looking at what we think are real world practice patterns here in this trial on top of background therapy compared to placebo where we think this can best inform Phase 3. And with that, I'll turn it over to Fady and Stuart.

    Prediction (one of UP, DOWN, SAME): SAME
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
Great. Thanks very much for taking my question. I wanted to talk a little bit more about oat milk. I think that's pretty amazing that it's driving half of your revenue growth in plant-based bidder and it's still a relatively small category. Can you talk about where that growth is coming from? Is that in more grocery or foodservice? And as we think about the capacity you have coming online over the next year or two, both the new Texas projects that you alluded to today, as well as into the other previously announced projects that haven't come online yet. How much of that new capacity is going to be related to oat?

    Prediction (one of UP, DOWN, SAME): SAME
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
Bill, do you want to speak to that?

    Prediction (one of UP, DOWN, SAME): SAME
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
I see what you mean. Yes. So, the performance fee that -- of the $20 million that you see, there was really only $5 million in Acadian and more -- about $15 million was from Campbell Global, which I guess we provide that breakup in our segment information, but you're right, that's performance, it doesn't get broken out. So, that's the breakup and of course, we have announced sale of Campbell Global and so what's included in the Quant and Solutions segment is only the $5 million performance fee, which as I mentioned earlier, is more sort of can think of it as an average run rate because 4Q would typically be higher. And there maybe times in earlier quarters, don't have performance fee.

    Prediction (one of UP, DOWN, SAME): SAME
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
Yeah, I think, we're away from that, whether it's only six months or not. I think our goal with respect to what we're doing and clearing is the creation of a platform both on the custody side for RIAs and on the clearing side for IBB's. The goal then is to take the software that we've developed and utilize that software for the end clients from an acquisition perspective, as well as to build on the existing trading platforms for retail that the firm has and bring those through in a very cohesive and user experience friendly way. And so that's just a lot of stuff to do. That's new businesses to build where the competitors are large and have big head starts. So, yeah Axos Clearing is about a month away from launching a really very nice RIA custody platform, it's quite comprehensive.
And so those are the types of things that are going on and so I'm just not particularly focused on, whether they make a million dollars on the segment or may lose a million dollars or make two million dollars, right now. What I'm focused on is the long-term benefits that that will generate and I -- what I hope to do is in a couple of years, instead of being sitting on $750 or $770 of zero cost deposits, I want to be sitting on $3 and $4 billion dollars of zero cost deposits and that's really the overall goal. And even if -- right now the deposit rate that Clearing gets in those deposits is very low -- and Clearing would be very profitable right now at a 2.5% rate. If said funds were 2.5%, Clearing would be super profitable.

    Prediction (one of UP, DOWN, SAME): SAME
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
Yes. Hey, this is Thor on for Paul. Thanks so much for taking the question. Can you talk a little bit about, on the 3831, how you expect the cadence of reimbursement to go in the second half, post launch?

    Prediction (one of UP, DOWN, SAME): DOWN
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
Thanks for taking my question. Maybe I'm just taking a step back. Could you talk a bit about just visibility in your lithium sales as we move into next year? Like we see all these announcements from big auto EMS and -- and -- and then smaller start-ups. And can you talk about how your salespeople attack those companies and then your lead time to that? And then maybe meet -- weaving in next year going from I think the Streets are like $850 million this year to over $1 billion of EBITDA next year.
Not to ask for guidance for '22, but just can you give us some puts and takes for growth in -- in '22 with -- with both volume and then how you think about pricing as well? Thank you.

    Prediction (one of UP, DOWN, SAME): SAME
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
Hi. Good afternoon, John, Matt thanks for taking the questions. Firstly on the guidance itself, we seem to have come around a full circle now. Last year around this time you change your guidance, raising capital and lowering royalties and contract revenues. So, I just want to understand from a time period point of view what is the enrollment on business discussions now and how comfortable are you with outlook, especially on the royalties and contract revenues side? That's one. And secondly, going back to Captisol while there was not much doubt that 2021 was a peak year for sales, at least in the near term, based on COVID and we all expected some deceleration the next year. Is your guidance revision signaling a faster pace of disintegration both for the second half and for 2022? Thanks.

    Prediction (one of UP, DOWN, SAME): DOWN
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
Well, were looking -- what were evaluating typically is a current coupon mortgage thats been originated at reasonably proximate to the current rates. So at a given point in time, were investing in a right underlying pool of mortgages that were originated in recent history at something around the then current coupon. Today, that current coupon is going to be in the high 2s, and were going to -- and it would cost about four times to buy it -- youd buy it. And that circumstance to what would model to about an eight, give or take, eight unlevered return, but our experience has actually been that the model to 8s have turned in to be more like 9s and above. So thats been our actual experience is that the actual receipt of cash flows have exceeded our expectations. It generally, generically, this origination that were investing in is going to look like bank or savings and loan originated paper generically. And its all Fannie -- and its all basically Fannie Mae back.

    Prediction (one of UP, DOWN, SAME): SAME
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
A.J., it's a good question. We have very high quality in both our home health and our hospice business, outpatient services as well. And so we do market directly to patients who are not connected with our senior living operations in any way, and we're grateful for that business and have intent to grow it.

    Prediction (one of UP, DOWN, SAME): UP
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
Yes. I mean, I think -- we believe there's probably some upside there. I think, as we look at this guidance, we feel it appropriate -- we feel it's good guidance, appropriate guidance given the amount of uncertainty that has persisted around COVID, right? With it -- we used to refer to the height of COVID in March and April, and now we actually had a higher emergence of COVID in December and January, right? So I think it reflects some of just that uncertainty. And clearly, the more back to normality we can get, the more opportunity there is. So I believe your perspective on that is correct that there could be some upside.

    Prediction (one of UP, DOWN, SAME): SAME
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
Hey, Pito, it's Preston. Just wanted to follow-up with on your Neurovascular question. I mean, I'd say overall, we're really pleased with the double-digit growth. And I think certainly, as we've seen in the past, that market has been accelerating. But I do think that with some of those launches that you mentioned, we are seeing share gains in that space as well. So those launches that we had throughout 2020 were really starting to capitalize as we've gotten into 2021. And so seeing good growth across a variety of those items, including flow to stents and our aspiration products.
As it relates to China, again, same thing as we brought technologies to those markets and been able to grow there, similar to how we've done in our other markets with Neurovascular. And so we really are looking forward to a strong year in total as we think about that Neurovascular business.

    Prediction (one of UP, DOWN, SAME): SAME
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
I'm sorry. On the business travel, our expectation is when we look at the mix of it, generally for us, it ends up being about 50-50. Depending on the quarter, you may see spikes going to two-thirds, one-third, either way. So it really is going to depend on when things open up. If we think about them in the back half of the year toward the summer months, it would obviously be indexed toward consumer, and as we head back into the fall, the ratio or index heads back to business.

    Prediction (one of UP, DOWN, SAME): DOWN
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
Unless, of course, god forbids, there's another variant or another COVID or another, but right now as we see based on what we know today, it's a soft landing. We get lost in the rounding by '23.

    Prediction (one of UP, DOWN, SAME): SAME